Glaxosmithkline was on the up after an independent panel in the US encouraged regulators to approve the company’s experimental therapy for a common type of blood cancer.
MARKET REPORT: Coronavirus vaccine talk lifts pharma’s big hitters
Something you may find interesting…
[recent_products per_page="4" columns="4" orderby="rand" order="rand"]